ArticleWomen's health reports (New Rochelle, N.Y.)2025
Clinical Analysis and Literature Review of 26 Patients with Hematological Malignancies During Pregnancy.
Article in Women's health reports (New Rochelle, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Leukemia during pregnancy and survivorship: gestational age-stratified multidisciplinary management framework.Clinical and experimental medicine · 2026Review
- An Account of Acute Myeloid Leukemia Complicating Pregnancy and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hematological malignancies during pregnancy are rare and lethal. Objective: The aim of this study is to demonstrate the incidence, clinical characteristics, treatment, and outcome of hematological malignancies diagnosed during pregnancy. Methods: This is a retrospective study of women who were diagnosed with hematological malignancies during pregnancy at an academic hospital between 2001 and 2021. Results: The incidence rate of 26 pregnant women with hematological malignancies in the pregnant patients admitted to the hospital was about 0.07%. Except for one patient who was diagnosed before pregnancy, the incidence rates of the first, second, and third trimesters of pregnancy were 12% (3/25), 48% (12/25), and 40% (10/25), respectively. Eleven out 26 patients (42.3%) finally gave birth to fetuses. In a long-term follow-up, the survival time of patients with leukemia in pregnancy was shorter than lymphoma ( Conclusion: This report provides a comprehensive description of maternal and infant outcomes and insights into the management of hematological malignancies during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.